Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

By Jennifer D. Gorman, K. Sack, John C. Davis. New England Journal of Medicine, 2002

666 citations recorded by the source corpus.

Subfields: Psychiatry and Mental health, Rheumatology

View Paper: https://www.semanticscholar.org/paper/493a94142d82cb8aaa7fd30dcd24b842ca7c0025

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. R. Landewé
2. D. Heijde
3. M. Dougados
4. J. Bradley
5. Jéhan-Michel Béhier
6. H. Zeidler
7. A. Wanders
8. I. Olivieri

Citations in the corpus

• TNF‐mediated inflammatory disease (2008, background): “A randomized, double-blind trial of etanercept showed that treatment with etanercept for 4 months resulted in rapid, significant and sustained improvement in patients with ankylosing spondylitis [111].”
• Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. (2005, background): “This picture changed after the demonstration that tumor necrosis factor (TNF)–blocking drugs, which inhibit radiographic progression in RA, are also highly effective in alleviating the symptoms of AS (20,21), and it is expected that as in RA, use of TNF-blocking drugs in patients with AS can inhibit”